Federated Hermes Inc. Sells 322,415 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Federated Hermes Inc. reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 45.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 389,393 shares of the biopharmaceutical company's stock after selling 322,415 shares during the period. Federated Hermes Inc. owned 0.31% of Halozyme Therapeutics worth $18,617,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Norges Bank bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $60,054,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after buying an additional 581,475 shares during the period. Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter worth $21,838,000. Vanguard Group Inc. boosted its holdings in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after acquiring an additional 386,618 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded up $0.68 during mid-day trading on Monday, hitting $60.90. 143,684 shares of the company were exchanged, compared to its average volume of 1,406,950. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business has a fifty day moving average of $60.22 and a 200 day moving average of $54.91. The company has a market capitalization of $7.52 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares of the company's stock, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock valued at $1,286,568 in the last three months. Corporate insiders own 2.40% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on HALO. Benchmark restated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.